KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.85

Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.

Liwei Shi, Xuefen Gao, Lili Huang, Zhao Gao, Juan Li, Bangwei Yu, Huilan Fan, Guohua Li, Yanxia Wang, Qi Li, Lin Yuan, Changgui Li, Zhaojun Mo, HPV1003 Study group, Li Shi, Ke Li, Min Ji, Ya-Lin Hu, Ling-Yun Zhou, Xue-Mei Yan, Jing-Jing Chen, Wei Li, Zi-Long Wang, Zhen Huang, Yu-Liang Zhao, Rong-Cheng Li, Yan-Ping Li, Nian-Min Shi, Qiang Lu, Bin He, Shi-Fang Wen, Dong-Zhang Yang, Guo-Gang Liu, Yan-Xia Cai, Wei-Jiang Cui, Jiang-Bing Zheng, Zhan-Bo Geng, Yan-Hua Xie, Yong-Biao Ren, Hai-Song Zhou

BMC Infect Dis 26(1) 248

PMID41413453
PMCIDPMC12870096
DOI10.1186/s12879-025-12064-1
发表日期2025-12-18
入排依据:The study is a Phase III randomized controlled trial with a drug (vaccine) intervention and reports original efficacy results. However, the primary efficacy endpoint (vaccine efficacy against CIN2+) is a proportion/risk reduction endpoint, not a time-to-event endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the specific cohort requirement for a time-to-event efficacy endpoint.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。
摘要

摘要

BACKGROUND: Affordable HPV vaccines are needed to accelerate elimination of cervical cancer. We evaluated the efficacy, safety, and immunogenicity of a recombinant bivalent human papillomavirus (HPV) vaccine composed of L1 virus-like particles (VLPs) for HPV 16 and HPV18 (HPV-2), produced in Pichia pastoris, in healthy Chinese women aged 18-30 years. METHODS: In this phase 3, double-blind, randomised, placebo-controlled trial conducted at 10 centres in China (Nov 2014-Jan 2020), participants were assigned 1:1 to receive three doses of HPV-2 or placebo at months 0, 2, and 6. The primary endpoint was efficacy against histopathology-confirmed cervical intraepithelial neoplasia grade 2 or higher (CIN2+) associated with HPV16/18 through 48 months. Secondary endpoints were safety (adverse events [AEs] within 1 month of any dose; serious AEs throughout follow-up) and immunogenicity (neutralising antibody titres and seroconversion at Month 7 in a predefined subset). RESULTS: Of 12,000 women enrolled, 11,999 received the first dose and 11,281 completed all three doses. Over 48 months, 17 CIN2 + cases occurred: 3 among vaccine recipients (n = 5190) versus 14 among placebo recipients (n = 5167), corresponding to vaccine efficacy of 78.6% (95% CI 23.3-96.1; p = 0.012). No vaccine-related serious AEs occurred. Solicited local AEs were mainly mild pain, reported by 25.9% of vaccinees and 7.9% of placebo recipients. Fever was the most common systemic AE (27.4% vs. 26.4%). In the immunogenicity subset, 99.7% (349/350) and 99.4% (348/350) of vaccinees were seropositive for HPV16 and HPV18 neutralising antibodies, respectively, at Month 7. CONCLUSIONS: Three doses of HPV-2 were well tolerated, highly immunogenic, and efficacious against CIN2 + up to 4 years post-vaccination, supporting further evaluation in the adolescent target population for HPV vaccination campaigns. TRIAL REGISTRATION: China Drug Trials Registry (CTR20140626; registered Sept 26, 2014; prospective). CLINICALTRIALS: gov (NCT02733068; registered April 11, 2016; secondary).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Flow chart. A total of 14,176 individuals were screened, and 12,000 were enrolled and randomized to receive either the bivalent HPV vaccine (HPV-2) or placebo. The safety set (SS) included all participants who received at least one dose of vaccine or placebo. Follow-up was conducted for 48 months. A subset of participants was selected for immunogenicity analysis; after exclusions, the per-protocol set for immunogenicity (iPPS) and the efficacy full analysis set (eFAS) and efficacy Per Protocol (ePPS) sets were defined for efficacy analyses
非 KM Figure
Fig. 2Kaplan–Meier estimates of efficacy endpoints in the Per Protocol Set. ( a ) Cumulative incidence of cervical intraepithelial neoplasia grade 2 or higher (CIN2⁺) up to 48 months after the first vaccination among participants receiving either the bivalent HPV-2 vaccine or placebo. The placebo group showed a higher cumulative incidence than the vaccine group. ( b ) Cumulative incidence of 6-month persistent infection with HPV-16 or HPV-18 through Month 36. Divergence between groups began around Month 12, with an early plateau in the HPV-2 group and continued event accumulation in the placebo group through Months 18–30. Both analyses were conducted in the efficacy Per Protocol Set (ePPS). Time is shown in months post-vaccination. Numbers at risk and cumulative event counts are presented below each plot
非 KM Figure
Fig. 3Solicited local and systemic reactogenicity to Placebo and HPV-2 with p value for differences between groups. Solicited local and systemic adverse events reported within 7 days after vaccination with bivalent human papillomavirus vaccine (HPV-2) or placebo. The percentages of participants experiencing each adverse event are shown. Local reactions include pain, itching, swelling, redness, and induration at the injection site. Systemic events include fever, headache, fatigue, nausea/vomiting, diarrhea, myalgia, and allergic conditions. Bars represent the proportion of participants with each event in the HPV-2 and placebo groups. P values were calculated for between-group comparisons using the chi-square or Fisher exact test. Abbreviations: AE, adverse event; HPV-2, bivalent human papillomavirus vaccine
非 KM Figure